Effect of Neoadjuvant Therapies on Soft Tissue Sarcomas with Tail-like Lesions: A Multicenter Retrospective Study.
chemotherapy
invasive front
myxofibrosarcoma
neoadjuvant therapy
radiotherapy
soft tissue sarcoma
tail-like lesion
undifferentiated pleomorphic sarcoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Aug 2021
02 Aug 2021
Historique:
received:
01
07
2021
revised:
27
07
2021
accepted:
28
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
8
8
2021
Statut:
epublish
Résumé
Several types of soft tissue sarcomas have peripheral infiltrative growth characteristics called tail-like lesions. The efficacy of neoadjuvant therapy for tumors with tail-like lesions has not been elucidated. From 2012 to 2019, we analyzed 36 patients with soft tissue sarcoma with tail-like lesions treated with neoadjuvant therapy, including chemotherapy, radiotherapy, or both. The effect of neoadjuvant therapy on the tail sign was investigated by analyzing the change in tail-like lesions during neoadjuvant therapy and histological responses. The median length of the tail-like lesion reduced from 29.5 mm at initiation to 19.5 mm after neoadjuvant therapy. The extent of shrinkage in tail-like lesions was related to the histopathological responses in the main part of the tumor. Complete disappearance of the tail-like lesion was observed in 12 patients; however, it was not related to achieving a microscopically negative margin. The oncologic outcomes did not significantly differ between cases with and without the complete disappearance of tail-like lesions. This study indicated that the shrinkage of tail-like lesions did not have a significant effect on complete resection or improvements of clinical outcomes. A more comprehensive evaluation is needed to elaborate on the surgical strategy.
Identifiants
pubmed: 34359802
pii: cancers13153901
doi: 10.3390/cancers13153901
pmc: PMC8345724
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Surg Oncol. 2013 Jan;20(1):80-6
pubmed: 22890594
Ann Surg Oncol. 2010 Oct;17(10):2578-84
pubmed: 20556523
Cancer. 2012 Jan 15;118(2):518-27
pubmed: 21717447
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):203-9
pubmed: 19679403
BMC Cancer. 2020 Sep 9;20(1):868
pubmed: 32907549
Lancet Oncol. 2012 Oct;13(10):1045-54
pubmed: 22954508
Ann Oncol. 2004 Nov;15(11):1667-72
pubmed: 15520069
J Natl Compr Canc Netw. 2020 Dec 02;18(12):1604-1612
pubmed: 33285515
J Clin Oncol. 1997 Jan;15(1):350-62
pubmed: 8996162
Anticancer Res. 2016 May;36(5):2339-44
pubmed: 27127141
Radiother Oncol. 2005 Apr;75(1):48-53
pubmed: 15948265
Sarcoma. 2012;2012:290698
pubmed: 22761544
Sarcoma. 2006;2006:21251
pubmed: 17496992
J Orthop Sci. 2018 Nov;23(6):1032-1037
pubmed: 30017714
Skeletal Radiol. 2013 Jun;42(6):809-18
pubmed: 23318907
Cancer. 2008 Aug 1;113(3):573-81
pubmed: 18521899
Lancet Oncol. 2017 Jun;18(6):812-822
pubmed: 28499583
Ann Diagn Pathol. 1999 Feb;3(1):1-10
pubmed: 9990107
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
AJR Am J Roentgenol. 2007 Feb;188(2):W193-8
pubmed: 17242227
Cancer Med. 2018 Apr;7(4):1560-1571
pubmed: 29479833
J Clin Oncol. 1998 Jan;16(1):197-203
pubmed: 9440743
Clin Orthop Relat Res. 2004 Feb;(419):165-72
pubmed: 15021149
Cancer. 1977 Apr;39(4):1672-85
pubmed: 192434
Jpn J Clin Oncol. 2009 Apr;39(4):271-3
pubmed: 19155282
Cancer. 1981 Mar 1;47(5):1005-22
pubmed: 7226034
Clin Orthop Relat Res. 2006 Sep;450:89-94
pubmed: 16801862
Cancer. 2002 May 1;94(9):2511-6
pubmed: 12015777
Jpn J Clin Oncol. 2014 Aug;44(8):765-9
pubmed: 24916336
Am J Surg Pathol. 1996 Apr;20(4):391-405
pubmed: 8604805
Cancers (Basel). 2019 Apr 10;11(4):
pubmed: 30974828
Skeletal Radiol. 2008 Dec;37(12):1085-90
pubmed: 18629459
J Surg Oncol. 2014 Nov;110(6):707-11
pubmed: 24975462
Eur Radiol. 2014 Aug;24(8):1749-57
pubmed: 24889995
Eur J Cancer. 2019 Mar;109:51-60
pubmed: 30690293
JAMA Oncol. 2018 Apr 1;4(4):483-492
pubmed: 29450452
Hum Pathol. 2004 May;35(5):612-21
pubmed: 15138937